Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
June 2023
Early Infection Risk in Patients with Systemic Lupus Erythematosus Treated with Rituximab or Belimumab from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): A Prospective Longitudinal Study
Lancet Rheumatol 2023;5:e284–92 doi:https://doi.org/10.1016/S2665-9913(23)00091-7
Data from a large prospective registry (BILAG-BR) highlight that, compared with standard of care, the serious infection risk was similar between rituximab and belimumab.
Keywords:
May 2022
Efficacy and Safety of Obinutuzumab in Systemic Lupus Erythematosus Patients with Secondary Non-response to Rituximab
Rheumatology 2022;00:1–5 DOI.org/10.1093/rheumatology/keac150
Arnold, et al. present the first case series reporting the efficacy and safety of obinutuzumab in patients with treatment refractory SLE. The results indicate that, for this group of patients with limited treatment approaches, obinutuzumab could be a potential option.
Keywords:
March 2022
Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004 index
Rheumatology (Oxford). 2022. Epub ahead of print doi: 10.1093/rheumatology/keab883
Easy-BILAG is a high-accuracy, time-efficient tool for recording BILAG-2004 disease activity in systemic lupus erythematosus (SLE).
Disease activity measurements in SLE are necessary for optimal patient care, treat-to-target approaches and clinical guidelines. However, administrative burden and potential frequency of errors with the current comprehensive disease activity instrument (BILAG-2004) limits its use in routine practice.